首页> 外文OA文献 >PCV2 PREDICTED OPTIMAL LIPID VALUE ATTAINMENT RATES WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN HISPANIC PATIENTS WITH MIXED DYSLIPIDEMIA

【2h】

PCV2 PREDICTED OPTIMAL LIPID VALUE ATTAINMENT RATES WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN HISPANIC PATIENTS WITH MIXED DYSLIPIDEMIA

机译：与混合性血脂异常的西班牙裔患者预测的PCV2最佳血脂值获得率与非铁纤维酸和他汀类药物相比应接受他汀类药物单药治疗的共同管理

代理获取

本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。

页面导航

著录项
引文网络
相似文献
相关主题

著录项

作者
Webb SF; Simko RJ;
展开▼
作者单位

展开▼
年度 2009
总页数
原文格式 PDF
正文语种
中图分类

相似文献

外文文献
专利

1. Evaluating optimal lipid levels in patients with mixed dyslipidemia following short- and long-term treatment with fenofibric acid and statin combination therapy: a post hoc analysis. [J] . Mohiuddin SM, Thakker KM, Setze CM, Current medical research and opinion . 2011,第5期

机译：评估非诺贝特酸和他汀类药物联合治疗短期和长期治疗后混合血脂异常患者的最佳脂质水平：事后分析。
2. Efficacy and safety of fenofibric acid co-administered with low- or moderate-dose statin in patients with mixed dyslipidemia and type 2 diabetes mellitus: results of a pooled subgroup analysis from three randomized, controlled, double-blind trials. [J] . Jones PH, Cusi K, Davidson MH, American journal of cardiovascular drugs: drugs, devices, and other interventions . 2010,第2期

机译：非诺贝特酸联合低剂量或中剂量他汀类药物在混合血脂异常和2型糖尿病患者中的疗效和安全性：来自三项随机，对照，双盲试验的汇总亚组分析结果。
3. Low-Density Lipoprotein Cholesterol Goal Attainment Rates by Initial Statin Monotherapy Among Patients With Dyslipidemia and High Cardiovascular Risk in Japan　― A Retrospective Database Analysis ― [J] . Tatsuya Umeda, Ai Hayashi, Akiko Harada, Circulation journal . 2018,第6期

机译：在日本血脂异常和高心血管风险患者中，最初的他汀类药物单一疗法低密度脂蛋白胆固醇目标达成率-回顾性数据库分析―
4. Liver Enzymes as Biomarkers for Hepatotoxicity of Statins in Patients with Dyslipidemia [C] . N. Velickova, M. Nateva, S. Stojanovska International Conference on Medical and Biological Engineering . 2020

机译：肝酶作为血脂血症患者肝毒性的生物标志物
5. Fenofibric acid: a new fibrate approved for use in combination with statin for the treatment of mixed dyslipidemia [O] . Peter Alagona Jr 2010

机译：非诺贝特酸：一种新的贝特类药物已批准与他汀类药物联合用于治疗混合性血脂异常
6. CV3 PREDICTED OPTIMAL LIPID VALUE ATTAINMENT WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN PATIENTS WITH MULTIPLE LIPID ABNORMALITIES [O] . Sorensen SV, Webb SF, Burge RT 2008

机译：CV3预测最佳脂蛋白值的确证与多脂异常患者的非纤维蛋白酸和他汀类药物单药治疗相比他汀类药物的共同管理

PCV2 PREDICTED OPTIMAL LIPID VALUE ATTAINMENT RATES WITH THE CO-ADMINISTRATION OF FENOFIBRIC ACID AND A STATIN COMPARED TO STATIN MONOTHERAPY IN HISPANIC PATIENTS WITH MIXED DYSLIPIDEMIA

著录项

引文网络

相似文献

相关主题

期刊订阅